NCT07831863尚未招募3 期
A Phase III, Open-label, Randomized-controlled, Multi-center Study of 7MW3711 Compared With Docetaxel in Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer Previously Treated With Platinum-based Chemotherapy and Immunotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 600
- 试验地点
- 1
- 主要终点
- Overall Survival
研究概览
简要总结
To compare the efficacy and safety of 7MW3711 versus docetaxel in patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) .
详细描述
A Phase III, Open-label, Randomized-controlled, Multi-center Study to Evaluate the Safety and Efficacy of 7MW3711 Compared with Docetaxel in Patients with Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer Previously Treated with Platinum-based Chemotherapy and Immunotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All trial participants or their legally acceptable representatives must sign the Ethics Committee-approved informed consent form before any screening procedures are initiated.
- •Aged 18 to 85 years (inclusive) at the time of signing the informed consent, regardless of gender.
- •ECOG performance status of 0 to
- •Histologically or cytologically confirmed unresectable locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). Mixed pathology including small cell lung cancer or other pathological components must be excluded.
- •Must have received prior first-line systemic anti-tumor therapy, including: a) platinum-based doublet chemotherapy; b) immunotherapy (including but not limited to monoclonal antibodies targeting PD-1, PD-L1, CTLA-4, or their bispecific antibodies).
- •Radiologically confirmed disease progression during or within 6 months after discontinuation of the most recent treatment regimen.
- •Archived tumor tissue samples must be provided.
- •Expected survival of ≥ 3 months.
- •At least one measurable lesion per RECIST v1.1 criteria at screening. For those with a clear history of radiotherapy, measurable lesions must be outside the radiation field or have shown clear progression after completion of radiotherapy.
- •Organ function of trial participants must meet certain criteria.
- •Subjects with reproductive potential must take effective contraceptive measures during the trial and for 180 days after the last dose. Female subjects must be confirmed non-pregnant before enrollment, and lactating females must stop breastfeeding, unless surgically sterilized, postmenopausal, or without reproductive potential.
- •Able to understand and comply with planned visits, treatment, laboratory tests, and other study procedures.
排除标准
- •Received radiotherapy, chemotherapy, or other anti-tumor treatments within 21 days before the first dose; received anti-tumor traditional Chinese medicine within 7 days; received other investigational drugs or devices not yet on the market within 28 days; previously received antibody-drug conjugates (ADCs) or docetaxel.
- •Positive for clinically significant driver gene mutations, including EGFR, KRAS, ALK, ROS1, BRAF, NTRK, MET, RET, HER
- •Persistent clinically significant toxicities of Grade ≥ 2 related to prior therapy (excluding alopecia and Grade 2 immune-related endocrine toxicities requiring stable doses of replacement therapy).
- •Trial participants with clinically symptomatic effusions requiring local therapy or repeated drainage (pleural effusion, ascites, pericardial effusion, etc.).
- •Underwent major surgery within 28 days before the first dose of study drug, excluding minor surgeries judged by the investigator as not affecting participation in the trial.
- •Received live vaccines within 28 days before the first dose of study drug, or plan to receive any live vaccines during the study period.
- •Clinically significant cardiovascular or cerebrovascular diseases within 6 months before the first study drug administration, including but not limited to: acute myocardial infarction, unstable angina, cerebrovascular accident, clinically significant ventricular arrhythmia, NYHA Class III/IV heart failure, QTcF ≥ 470 ms (female) / 450 ms (male), history of long QT syndrome, LVEF < 50% or severe wall motion abnormality, uncontrolled hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg), or other unsuitable arrhythmias.
- •History of pulmonary disease requiring steroid therapy; active pulmonary tuberculosis within 1 year before the first study drug administration; pulmonary embolism, severe asthma, or severe chronic obstructive pulmonary disease within 3 months; autoimmune or inflammatory diseases involving the lungs; history of prior pneumonectomy on one side.
- •History of gastrointestinal perforation or fistula within 6 months before the first study drug administration, or active gastric/duodenal ulcer, ulcerative colitis, or other gastrointestinal diseases that the investigator considers may cause bleeding or perforation.
- •Uncontrolled active bleeding or known bleeding tendency. If imaging shows tumor invasion of major blood vessels or unclear boundaries, or if the investigator judges that the tumor is highly likely to invade important blood vessels during the subsequent study period causing fatal massive bleeding.
- •History of deep vein thrombosis, pulmonary embolism, or any other severe thromboembolic event within 3 months before the first study drug administration; portal vein tumor thrombus involving both the main trunk and bilateral first-order branches, or involving both the main trunk and superior mesenteric vein, or inferior vena cava tumor thrombus.
- •Presence of any of the following infections: ① Hepatitis B virus; ② Hepatitis C virus; ③ Human immunodeficiency virus; ④ Active Mycobacterium tuberculosis infection; ⑤ Other active infections requiring systemic intravenous anti-infective treatment occurring within 14 days before the first study drug administration; ⑥ Active syphilis infection.
- •Subjects with central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects who have received treatment for brain metastases or have small, asymptomatic, incidental, untreated lesions may be considered for participation, provided that clinical symptoms are stable for at least 4 weeks before study drug administration, no disease progression is confirmed by imaging within 4 weeks before the first dose, all neurological symptoms have completely resolved, no evidence of new or enlarged brain metastases, and radiation, surgery, or steroid therapy was discontinued at least 28 days before the first dose of study treatment. Carcinomatous meningitis and meningeal compression should be excluded regardless of clinical stability.
- •Other malignancies within 3 years before the first dose of study drug, except for cured cancers.
- •Active autoimmune diseases within 6 months before the first dose of study drug. Subjects with hypothyroidism requiring only stable doses of replacement therapy or skin diseases not requiring systemic treatment are eligible.
- •Use of systemic immunosuppressive agents within 2 weeks before the first dose of study drug, excluding: topical glucocorticoids, physiological doses of systemic glucocorticoids, or glucocorticoids used as prophylaxis for hypersensitivity reactions.
- •Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- •History of drug abuse or psychiatric illness, or suspected allergy or intolerance to the study drug or any of its components.
- •Other conditions judged by the investigator as unsuitable for participation in the study.
研究组 & 干预措施
7MW3711
Experimental
Participants will receive intravenous (IV) infusion of 7MW3711 as per protocol
干预措施: 7MW3711 (Drug)
Docetaxel
Active Comparator
Participants will receive intravenous (IV) infusion of Docetaxel as per protocol
干预措施: Docetaxel (Drug)
结局指标
主要结局
Overall Survival
时间窗: Up to 34 months
Time from the date of randomization until the date of death from any cause.
次要结局
- Objective Response Rate per investigator(Up to 34 months)
- Progression Free Survival per investigator(Up to 34 months)
- Duration of Response per investigator(Up to 34 months)
- Disease Control Rate per investigator(Up to 34 months)
- Time to response per investigator(Up to 34 months)
- Incidence of adverse events(Up to 34 months)
- SAE（Serious adverse event）(Up to 34 months)
- Immunogenicity of 7MW3711(Up to 34 months)
- Quality of life (QoL) assessed by EORTC QLQ-C30(Up to 34 months)
- Quality of life (QoL) assessed by EQ-5D-5L(Up to 34 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid TumorsNCT07466160Mabwell (Shanghai) Bioscience Co., Ltd.280
已完成
2 期
MK-7684A (new drug co-formulation of pembrolizumab with an anti-TIGIT) plus docetaxel works to help stop or slow down the growth of your non-small cell lung cancer (NSCLC) compared to docetaxel alone2022-501252-28-00Merck Sharp & Dohme LLC150
招募中
2 期
Safety and preliminary effectiveness of BNT327, an investigational therapy for patients with non-small cell lung cancer in combination with chemotherapy following chemoimmunotherapyNon-small Cell Lung Cancer2024-518279-80-00BioNTech SE10
已完成
3 期
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200)Previously treated locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation2023-508214-42-00Amgen Inc.362
尚未招募
2 期
A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）NCT07609251Sinocelltech Ltd.90